MetabolicFDA Approved

Semaglutide

Also known as Ozempic · Wegovy · Rybelsus

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

Overview

Semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered for once-weekly dosing via fatty-acid acylation and amino-acid substitutions that resist DPP-4 degradation. Approved by the FDA for type 2 diabetes (2017) and chronic weight management (2021).

Mechanism

GLP-1 receptor agonism → glucose-dependent insulin secretion, slowed gastric emptying, central appetite suppression.

Research areas

Type 2 diabetes
Obesity
MASH
Cardiovascular risk reduction

Related peptides

Tirzepatide

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

View

Retatrutide

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

View

Cagrilintide

Long-acting amylin analog studied alongside semaglutide as CagriSema.

View